AmCad BioMed Corporation (TPEX:4188)

AmCad BioMed Statistics

Total Valuation

AmCad BioMed has a market cap or net worth of TWD 924.66 million. The enterprise value is 632.46 million.

Market Cap	924.66M
Enterprise Value	632.46M

Important Dates

The next estimated earnings date is Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

AmCad BioMed has 63.33 million shares outstanding. The number of shares has increased by 14.80% in one year.

Current Share Class	63.33M
Shares Outstanding	63.33M
Shares Change (YoY)	+14.80%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	6.64%
Owned by Institutions (%)	0.95%
Float	32.93M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	21.25
PB Ratio	1.52
P/TBV Ratio	2.00
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-13.06
EV / Sales	14.54
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-15.00

Financial Position

The company has a current ratio of 16.46, with a Debt / Equity ratio of 0.01.

Current Ratio	16.46
Quick Ratio	14.98
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.14
Interest Coverage	-670.24

Financial Efficiency

Return on equity (ROE) is -8.91% and return on invested capital (ROIC) is -6.93%.

Return on Equity (ROE)	-8.91%
Return on Assets (ROA)	-6.70%
Return on Invested Capital (ROIC)	-6.93%
Return on Capital Employed (ROCE)	-11.70%
Revenue Per Employee	1.28M
Profits Per Employee	-1.42M
Employee Count	34
Asset Turnover	0.07
Inventory Turnover	0.73

Taxes

Income Tax	-15,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -31.93% in the last 52 weeks. The beta is 0.40, so AmCad BioMed's price volatility has been lower than the market average.

Beta (5Y)	0.40
52-Week Price Change	-31.93%
50-Day Moving Average	15.05
200-Day Moving Average	15.20
Relative Strength Index (RSI)	47.09
Average Volume (20 Days)	49,525

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, AmCad BioMed had revenue of TWD 43.51 million and -48.44 million in losses. Loss per share was -0.76.

Revenue	43.51M
Gross Profit	22.81M
Operating Income	-71.72M
Pretax Income	-56.84M
Net Income	-48.44M
EBITDA	-61.29M
EBIT	-71.72M
Loss Per Share	-0.76

Balance Sheet

The company has 381.88 million in cash and 5.95 million in debt, with a net cash position of 375.92 million or 5.94 per share.

Cash & Cash Equivalents	381.88M
Total Debt	5.95M
Net Cash	375.92M
Net Cash Per Share	5.94
Equity (Book Value)	608.83M
Book Value Per Share	8.29
Working Capital	406.76M

Cash Flow

In the last 12 months, operating cash flow was -41.78 million and capital expenditures -373,000, giving a free cash flow of -42.16 million.

Operating Cash Flow	-41.78M
Capital Expenditures	-373,000
Free Cash Flow	-42.16M
FCF Per Share	-0.67

Margins

Gross margin is 52.41%, with operating and profit margins of -164.82% and -111.32%.

Gross Margin	52.41%
Operating Margin	-164.82%
Pretax Margin	-130.63%
Profit Margin	-111.32%
EBITDA Margin	-140.86%
EBIT Margin	-164.82%
FCF Margin	n/a

Dividends & Yields

AmCad BioMed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.80%
Shareholder Yield	-14.80%
Earnings Yield	-5.24%
FCF Yield	-4.56%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AmCad BioMed has an Altman Z-Score of 22.54 and a Piotroski F-Score of 1.

Altman Z-Score	22.54
Piotroski F-Score	1